Sarepta Therapeutics Stock Surges 43% YTD: How to Play the Stock? [Yahoo! Finance]
Sarepta Therapeutics, Inc. (SRPT)
Last sarepta therapeutics, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investorrelations.sarepta.com/events-and-presentations
Company Research
Source: Yahoo! Finance
The stock has also underperformed the sector and the S&P 500 during the same period, as shown in the chart below. SRPT's shares are trading above the 50 and 200-day moving averages. Image Source: Zacks Investment Research The surge in the stock price can be attributed to the encouraging sales performance of Duchenne muscular dystrophy (DMD) gene therapy Elevidys. Currently, Elevidys is the first and only one-shot gene therapy for DMD in the United States. Since its commercial launch in June 2023, the therapy has demonstrated blockbuster potential. Despite initially being approved in the country with a confined label to treat ambulatory DMD patients aged four to five years, the therapy added more than $200 million to Sarepta's top line last year. It was only after Elevidys' approval that the company crossed the billion-dollar threshold in annual net product sales for the first time in 2023. In June, the FDA expanded Elevidys' label to treat all DMD patients aged four years an
Show less
Read more
Impact Snapshot
Event Time:
SRPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRPT alerts
High impacting Sarepta Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SRPT
News
- Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceBusiness Wire
- Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- High Growth Tech Stocks To Watch In December 2024 [Yahoo! Finance]Yahoo! Finance
- High Growth Tech Stocks To Watch In December 2024 [Yahoo! Finance]Yahoo! Finance
- High Growth Tech Stocks To Watch For Potential Opportunities [Yahoo! Finance]Yahoo! Finance
SRPT
Earnings
- 11/6/24 - Beat
SRPT
Sec Filings
- 12/30/24 - Form 4
- 12/16/24 - Form 4
- 12/12/24 - Form 144
- SRPT's page on the SEC website